StockMarketWire.com - Verona Pharma said it had recorded positive interim efficacy and safety data from part one of a two-part clinical trial of a dry powder inhaler for chronic obstructive pulmonary disease.

The positive data supported initiation of the second part of the Phase 2 trial to evaluate the ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment.

In the first part of the trial, involving 37 patients, interim efficacy and safety data showed a statistically significant and clinically meaningful increase in lung function compared to placebo.

'Positive data from this and future studies with inhaler formulations could dramatically expand the clinical utility and commercial opportunity for ensifentrine not only in the treatment of COPD, but potentially in other respiratory diseases such as asthma,' chief executive Jan-Anders Karlsson said.


At 9:18am: [LON:VRP] Verona Pharma PLC share price was +3.5p at 55p



Story provided by StockMarketWire.com